Anti-Actin (AA128, Beyotime), anti-GPR109a (ab81825, Abcam, USA), anti-GPR43 (DF2746, Affinity Biosciences, USA), anti-H3 (anti-total histone H3, 4499, Cell Signaling Technology, CST, USA), anti-Ace-H3 (anti-pan-acetyl histone H3, 61637, Active Motif, USA), anti-p-AMPK (2535, adenosine monophosphate activated protein kinase, CST, USA), anti-p-ACC (11818, p-acetyl-CoA carboxylase, CST), anti-IR (anti-insulin receptor, ab5500, Abcam), anti-IRS-1 (anti-insulin receptor substrate-1, ab46800, Abcam), and anti-GLP-1R (NBP1-97308, Novus Biologicals, USA) were used in our study
G.Denise RobertsonM.FieldingB
Glucagon-like peptide-1 receptor agonist use is associated with increased rates of acne vulgaris diagnosis in nondiabetic obese women but not men: a retrospective cohort study
Wegovy, the only form of semaglutide approved for weight loss, is intended for use by those with either of the following: a BMI of 27 or greater and one weight-related health condition, such as high blood pressure a BMI of 30 or greater Both Ozempic and Rybelsus are intended for use in people with type 2 diabetes
sleep-regulation pathway research, neuropeptide models, circadian rhythm studies
